BioNTech SE has announced plans to acquire CureVac, a clinical-stage biotechnology company specialising in mRNA-based therapies for cancer and infectious diseases. The acquisition is to be executed through an all-stock public exchange offer, with each CureVac share exchanged for approximately $5.46 in BioNTech American Depositary Shares, valuing the transaction at $1.25 billion.

Through the deal, BioNTech aims to integrate CureVac’s mRNA design, delivery, and manufacturing capabilities to enhance its own development efforts in cancer immunotherapy. The acquisition supports BioNTech’s broader strategy to strengthen its position in the mRNA therapeutic landscape.